Top in endocrinology: Menopausal hormone therapy, bariatric surgery
Click Here to Manage Email Alerts
New data showed that hormone therapy during menopause did not increase the risk for CVD or type 2 diabetes among middle-aged postmenopausal women. A report on the findings was the top story in endocrinology last week.
The second top story of the week included data that showed bariatric surgery significantly reduced major adverse liver outcomes and cardiovascular events in adults with nonalcoholic steatohepatitis and obesity compared with nonsurgical treatment. Bariatric surgery was also associated with significantly greater reductions in body weight and HbA1c.
Read these and more top stories in endocrinology below:
Menopausal HT does not increase risks for CVD, type 2 diabetes for middle-aged women
Menopausal hormone therapy does not affect risks for cardiovascular disease or type 2 diabetes, according to findings from a study of middle-aged postmenopausal women in South Korea published in Menopause. Read more.
Bariatric surgery provides ‘huge’ reduction in major adverse liver outcomes, CV events
Adults with nonalcoholic steatohepatitis and obesity have a much lower risk for a major adverse liver outcome or major adverse cardiovascular event if they undergo bariatric surgery vs. nonsurgical treatment, according to study data. Read more.
Clinicians must advocate, take action to eliminate weight stigma
Health care professionals must be advocates for reducing weight stigma by helping to develop policies and to eliminate weight discrimination in their clinics, according to a speaker at ObesityWeek 2021. Read more.
Higher total bone density may reduce odds for CVD in women
Women with a bone mineral density greater than 1.085 g/cm2 may have less risk for cardiovascular disease than those with a lower BMD, according to study data published in Nutrition, Metabolism & Cardiovascular Diseases. Read more.
Metrics improve for US children with type 1 diabetes using CGM in first year of COVID-19
A cohort of U.S. children with type 1 diabetes had a decrease in mean glucose level and glucose management indicator during the first year of the COVID-19 pandemic compared with the prior year, according to study data. Read more.